NSAV IN TALKS TO ACQUIRE MAJOR STAKE IN LEADING LIVER PURIFIER MANUFACTURER
Press releases

NSAV IN TALKS TO ACQUIRE MAJOR STAKE IN LEADING LIVER PURIFIER MANUFACTURER

August 24, 2018/Prexly/ — Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that the Company is in the final stages of negotiations to acquire a major stake in New Jersey based, T.C. High Tech Herb, Inc., which manufactures one of the nation’s leading liver purifier supplements. The product, known commercially as LIVER PURIFIER. To date, over US$ 5 million of LIVER PURIFIER products have been sold. LIVER PURIFIER is trademarked in the U.S. and NSAV is currently in the process of registering additional U.S. and worldwide trademarks. In addition, the Company has recently begun the process of obtaining U.S. Patent protection and FDA registration for LIVER PURIFIER. The Company anticipates completing the acquisition next week.

NSAV also announced today that it plans a cbd oil based version of the LIVER PURIFIER. Further details will be announced in the coming weeks.

LIVER PURIFIER was formulated by well-known U.S. hepatologists, biologists and botanists, who have spent over six years on research and experiments. Studies conducted by world renowned University Medical Center in Washington D.C. have proven LIVER PURIFIER’S effectiveness and no adverse side effects were seen in the study.

In related news, NSAV has engaged the prestigious London auditor and accounting firm, Wilton Group ( https://www.wiltongroup.com/valuations ) to provide a commercial valuation of LIVER PURIFIER. Wilton Group is also NSAV’s accountant, as well as providing accounting services to other public companies. In addition, Wilton Group is a registered service provider with OTC Markets.

If concluded, the LIVER PURIFIER acquisition will be the third major medical deal that NSAV has completed in the past eight months. In December, the Company’s subsidiary, Shanghai based Vital Strategic Research Institute (VSRI), signed an agreement with Eli Lilly and Company ( www.lilly.com ) Under the terms of the agreement, VSRI will provide Eli Lilly with an assessment of Cardio Vascular Disease (CVD) among newly diagnosed diabetes patients at increased risk of CVD in China. China is facing the largest diabetes epidemic in the world with around 11 percent of its population suffering from the metabolic illness, while nearly 36 percent are pre-diabetic. CVD in China has also reached epidemic proportions, with over 200 million Chinese suffering from the world’s leading cause of death. More details on the Eli Lilly transaction, as well as the signed agreement with Eli Lilly, can be found in the Company’s SEC 8-K filing, which can be located at the link below.

https://www.otcmarkets.com/filing/html?id=12440904&guid=NHVEUn0Vr9IZQth

NSAV subsidiary, VSRI is a medical research firm with a long history of expertise in design, clinical trials and global research. VSRI has collaborated with pharmaceutical giants such as Pfizer and Bristol-Myers Squibb.

James Tilton, president of NSAV stated, “I am thrilled that we are close to completing another major deal for our medical division. It is extremely rewarding to be the CEO of a company that is not only succeeding from a business standpoint, but also saving lives.”

NSAV’s vision is the establishment of a fully integrated technology and software company that provides turnkey technological and software solutions to the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services, patents and trademarks and information technology.

For further information, please contact NSAV at info@nsavholdinginc.com .

The NSAV corporate email address is info@nsavholdinginc.com

The NSAV corporate website can be accessed at http://nsavholdinginc.com

The NSAV Twitter account can be accessed at  https://twitter.com/NSAV_MJTechCo

The NSAV Facebook account can be accessed at  https://www.facebook.com/NSAVHolding

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.